Cathie Wood: Market Often Underestimates the Power of Technological Innovation to Reshape the Macro Landscape, Inflation Could Surprisingly Taper
BlockBeats News, May 9th, Cathie Wood, also known as "Wood Sister," shared her market views, pointing out that a key signal at the moment is: despite a significant increase in oil prices over the past three months, the yield curve is still flattening. This is contrary to the typical pattern in the traditional economic cycle where an "energy shock is monetized by the Fed," leading to a steepening of the curve, as the Fed has not monetized this energy shock. The bond market may be preemptively pricing in the potent deflationary effect brought about by AI.
Cathie Wood stated that the cost of training AI models has dropped significantly, with the cost of inference decreasing even faster. At the same time, productivity growth is accelerating below official data, and unit labor costs remain low. While the mainstream market narrative focuses on tariffs, deficits, and structural high inflation, the deflationary forces of innovation are gathering strength. Predicting that inflation may unexpectedly decrease in the next 6-9 months, which will have a profound positive impact on interest rates and long-duration equity assets, she warned that the market often underestimates the speed and scale at which technological innovation reshapes the macro environment.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment
According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.
GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions
Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.
BUZZ-3M India shares fall to 19-month low due to quarterly profit decline
Anthropic (ANT.US) to launch IPO roadshow next week, valuation may shrink from 1.5 trillion dollars to 1 trillion dollars! The AI capital feast faces a test.
After the AI sell-off, major investors are questioning whether Anthropic can go public at a $1.5 trillion valuation, or if it will be reduced to around $1 trillion. Fundraising may also decrease from $100 billion to $80 billion.
